Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 8/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751688 | 0.86 | EPHX2 (0.44) | EPHX2GGPS1GBA1HDAC1HRH4 | |
| SCHEMBL25734930 | 0.84 | GGPS1 (0.45) | EPHX2GGPS1HDAC1 | |
| SCHEMBL26382134 | 0.84 | EPHX2 (0.48) | EPHX2GBA1HDAC1 | |
| SCHEMBL24469396 | 0.83 | EPHX2 (0.41) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL25735012 | 0.82 | GGPS1 (0.40) | EPHX2GGPS1HDAC1CYP19A1 | |
| SCHEMBL25735014 | 0.82 | GGPS1 (0.40) | EPHX2GGPS1HDAC1CYP19A1 | |
| SCHEMBL20362415 | 0.81 | EPHX2 (0.47) | EPHX2GGPS1GBA1HDAC1HRH4 | |
| SCHEMBL30237065 | 0.80 | L3MBTL1 (0.55) | EPHX2HDAC1HRH4HRH3CYP19A1 | |
| SCHEMBL30236057 | 0.80 | EPHX2 (0.44) | EPHX2GGPS1GBA1HDAC1HRH4 | |
| SCHEMBL25734929 | 0.79 | GGPS1 (0.40) | EPHX2GGPS1HDAC1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | EPHX2 1864/4885GGPS1 2039/4885GBA1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.